Patents Assigned to Amorfix Life Sciences, Ltd
-
Patent number: 8828389Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.Type: GrantFiled: December 7, 2011Date of Patent: September 9, 2014Assignee: Amorfix Life Sciences Ltd.Inventor: Neil Cashman
-
Patent number: 8778885Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1.Type: GrantFiled: June 8, 2011Date of Patent: July 15, 2014Assignee: Amorfix Life Sciences Ltd.Inventors: Neil R. Cashman, Avijit Chakrabartty, Rishi Rakhit, Joachim Bernhard Ostermann
-
Patent number: 8709422Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2).Type: GrantFiled: December 24, 2010Date of Patent: April 29, 2014Assignee: Amorfix Life Sciences Ltd.Inventors: Neil R. Cashman, Joachim Bernhard Ostermann, Avijit Chakrabartty, Rishi Rakhit
-
Patent number: 8513387Abstract: The invention provides binding proteins that bind to misfolded or monomeric SOD1, and not to native homodimeric SOD1. The invention also includes methods of diagnosing, detecting or monitoring amyotrophic lateral sclerosis in a subject. In addition, the invention provides methods of identifying substances for the treatment or prevention of amyotrophic lateral sclerosis and kits using the binding proteins of the invention.Type: GrantFiled: July 21, 2010Date of Patent: August 20, 2013Assignees: Amorfix Life Sciences Ltd., University Health NetworkInventors: Avijit Chakrabartty, Rishi Rakhit, Neil R. Cashman
-
Patent number: 8075891Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.Type: GrantFiled: June 2, 2010Date of Patent: December 13, 2011Assignee: Amorfix Life Sciences Ltd.Inventor: Neil Cashman
-
Publication number: 20110124018Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent.Type: ApplicationFiled: October 22, 2010Publication date: May 26, 2011Applicant: AMORFIX LIFE SCIENCES LTD.Inventors: Neil Cashman, Marty Lehto
-
Publication number: 20110020358Abstract: The invention provides binding proteins that bind to misfolded or monomeric SOD1, and not to native homodimeric SOD1. The invention also includes methods of diagnosing, detecting or monitoring amyotrophic lateral sclerosis in a subject. In addition, the invention provides methods of identifying substances for the treatment or prevention of amyotrophic lateral sclerosis and kits using the binding proteins of the invention.Type: ApplicationFiled: July 21, 2010Publication date: January 27, 2011Applicants: AMORFIX LIFE SCIENCES LTD., UNIVERSITY HEALTH NETWORKInventors: Avijit Chakrabartty, Rishi Rakhit, Neil R. Cashman
-
Patent number: 7794692Abstract: The invention provides binding proteins that bind to misfolded or monomeric SOD1, and not to native homodimeric SOD1. The invention also includes methods of diagnosing, detecting or monitoring amyotrophic lateral sclerosis in a subject. In addition, the invention provides methods of identifying substances for the treatment or prevention of amyotrophic lateral sclerosis and kits using the binding proteins of the invention.Type: GrantFiled: December 1, 2006Date of Patent: September 14, 2010Assignees: Amorfix Life Sciences Ltd., University Health NetworkInventors: Avijit Chakrabartty, Neil R. Cashman, Rishi Rakhit
-
Patent number: 7763710Abstract: The invention relates to a composition for eliciting an immune response in an animal to produce an antibody that binds selectively to an amyotrophic lateral sclerosis (ALS)-specific epitope.Type: GrantFiled: September 24, 2008Date of Patent: July 27, 2010Assignee: Amorfix Life Sciences Ltd.Inventor: Neil Cashman
-
Publication number: 20090098151Abstract: The invention relates to a composition for eliciting an immune response in an animal to produce an antibody that binds selectively to an amyotrophic lateral sclerosis (ALS)-specific epitope.Type: ApplicationFiled: September 24, 2008Publication date: April 16, 2009Applicant: AMORFIX LIFE SCIENCES LTD.Inventor: Neil Cashman
-
Patent number: 7439324Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.Type: GrantFiled: March 3, 2006Date of Patent: October 21, 2008Assignee: Amorfix Life Sciences, LtdInventor: Neil Cashman
-
Publication number: 20070003977Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent.Type: ApplicationFiled: August 20, 2004Publication date: January 4, 2007Applicant: Amorfix Life Sciences LtdInventors: Neil Cashman, Marty Lehto
-
Publication number: 20060246517Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.Type: ApplicationFiled: March 3, 2006Publication date: November 2, 2006Applicant: Amorfix Life Sciences LtdInventor: Neil Cashman